SUBSCRIBE: eNewsletter
The approval is based on data from two randomized, sham injection-controlled, double-masked phase 3 clinical trials with patient follow-up for 3 years.
Here: highlights of some of the studies that will be presented at the American College of Rheumatology 2018 Annual Meeting in Chicago from October 19 to 24.
Cognitive behavioral therapy for insomnia may slow or even reverse the atrophy of cortical gray matter associated with fibromyalgia.
The approval is based on data from the JIGSAW-118 study, which was designed to determine the appropriate dosing regimen of Actemra SC in children with SJIA.
Patients with obstructive sleep apnea are at increased risk for gout, even beyond the first year after the sleep disorder is diagnosed.
Swedish researchers found a 30% increase in the risk of fractures—independent of the degree of weight loss.
Fish oil supplements proved no better than placebo at relieving dry eye disease.
The goal of the study: to identify young patients at risk before any clinical symptoms develop.
Here’s a brief look at medications for rheumatologic disorders that were approved or granted a new indication in 2018.
A potential non-immunosuppressive treatment option for patients with diffuse cutaneous systemic sclerosis.
We've noticed that you're using an ad blocker
Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.
